Abstract

Purpose. The objective of this study is to investigate the effect of dual blockage of renin-angiotensin system (RAS) on renal kallikrein expression and inflammatory response in diabetic nephropathy (DN). Methods. Rats were randomly divided into 5 groups with 10 rats in each group: normal control; DN model induced by high fat and high sucrose diets; and DN treated with either benazepril 10 mg/kg/d, irbesartan 30 mg/kg/d, or both. After 8-week treatment, we examined changes in the kidney histopathology, function and immunohistochemical stain of kallikrein, macrophage marker CD68, and profibrotic markers transforming growth factor- (TGF-) β and α-smooth muscle action (SMA). Results. DN rats showed enlarged kidneys with glomerulosclerosis, interstitial chronic inflammation and fibrosis, and proteinuria. All the pathological damage and functional impairments were improved after the RAS blockades (all P < 0.05). Compared with monotherapy, combined treatment further alleviated the kidney impairments in parallel to increased tubular immunoreactivity for kallikrein and decreased immunopositive cells for CD68, TGF-β, and α-SMA. Conclusion. The renoprotective effects of the dual RAS blockade in diabetic nephropathy may be attributed to improved tubular kallikrein expression and interstitial inflammatory response.

Highlights

  • Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes mellitus (DM) and a leading cause of end-stage renal disease (ESRD) [1]

  • The aim of the present study was to investigate the effect of combined intervention with angiotensin-converting enzyme inhibitors (ACEI)-benazepril and ARBirbesartan on experimental diabetic nephropathy (DN) rats

  • This study shows tubular kallikrein activation and inflammatory amelioration likely underlying the renoprotective effects of renin-angiotensin system (RAS) blockades in diet-induced diabetic nephropathy

Read more

Summary

Introduction

Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes mellitus (DM) and a leading cause of end-stage renal disease (ESRD) [1]. China currently has approximately 100 million adults with type diabetes and 150 million people with prediabetes [2, 3]. 120 million Chinese adults may suffer from chronic kidney disease manifested predominantly as albuminuria [4]. Albuminuria is the major determinant of DN and an important risk factor for cardiovascular disease in patients with diabetes. Hospitalized Chinese patients with type-2 diabetes showed 44% of microalbuminuria, 12% of macroalbuminuria, and 17% of cardiovascular disease [5]. Type-2 diabetes and chronic kidney disease have become major public health problems in China

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call